FridayJun 18, 2010 10:42 am

Cellceutix Corp. (CTIX.OB): The Baby Blue Chip Presents a Great Investment Opportunity

With over four thousand NASDAQ Bulletin Board listed companies, it can be a bit of a task to research and find the true jewels that present great investment opportunities. No need to keep looking as we are bringing you one today. Cellceutix Corporation trades on the NASDAQ Bulletin Board under the ticker CTIX and is emerging as an industry leader in both autism and multi-drug resistant cancers. When finding a solid biotechnology investment, it is imperative to research three primary requirements: history, pipeline and potential. We will take a look at these three and how Cellceutix Corporation measures up as…

Continue Reading

FridayJun 18, 2010 10:11 am

Keegan Resources Inc. (KGN) Finds Excellent Test Results in Ghana, West Africa

For those interested in investments that hold very large potential and a certain amount of risk, African mining opportunities may be one way to go. The opportunities available are many and the rewards great, but one is never quite sure what will or may occur in a changing economic and political environment. Some regions are quite safe while others present significant challenges. Making an assessment and an informed decision is the key. Losing everything is possible but making a fortune could become reality. Keegan Resources Inc., a junior natural resources company, explores and develops natural resource opportunities primarily in Ghana,…

Continue Reading

FridayJun 18, 2010 9:12 am

China MagneGas Corp. (MNGA.OB) Refinery Almost Complete

MagneGas Corp. is the producer of MagneGas, a natural gas alternative and metal working fuel. MagneGas is made from liquid wastes such as sewage, sludge, manure, and certain industrial and oil-based liquid wastes. The company's patented plasma arc flow process gasifies liquid waste, creating a clean burning fuel that is essentially interchangeable with natural gas, but with lower greenhouse gas emissions. On June 17th, the company announced that its construction of the 200 kilowatt 'plasma arc flow' refinery ordered by Beijing-based DDI Industry International is on schedule and nearing completion. MagneGas expects DDI to inspect the unit in person in…

Continue Reading

ThursdayJun 17, 2010 3:44 pm

Green Energy Live, Inc. (GELV.OB) Acquires Peck Electric as Wholly Owned Subsidiary with Strong Footing in Clean Energy Industry

Green Energy Live Inc., a clean energy company engaged in the development of sustainable biomass-to-energy conversion solutions for the U.S. livestock industry, today announced it has extended its letter of intent to acquire 100 percent of the stock of Peck Electric Inc., Vermont's leading provider of electrical contracting services. Green Energy Live noted that Peck has been successful in maintaining and accelerating its electrical services business with strong and consistent revenue, longstanding relationships with key customers, and has taken advantage of opportunities for expansion within the clean energy industry. Peck’s workforce has experience in all aspects of electrical wiring for…

Continue Reading

ThursdayJun 17, 2010 3:42 pm

MKTG Inc. (CMKG) to Voluntarily Delist from Nasdaq to OTCBB

MKTG INC, a NY-based alternative media and marketing services company, recently reported that trading in its common stock is expected to move from the Nasdaq Capital Market to the OTC Bulletin Board effective June 25, 2010. The voluntary decision rests on the fact that the company is in not in compliance with Nasdaq's rules that it maintain a minimum bid price of $1; in response, the company today notified the Nasdaq Stock Market of its intent to voluntarily delist its common stock from Nasdaq, and announced that it will file a Form 25 with the Securities and Exchange Commission to…

Continue Reading

ThursdayJun 17, 2010 3:40 pm

Kun Run Biotechnology (KURU.OB) Obtains Marketing Approval for Hepatitis-B Treatment from China State Food and Drug Administration

Kun Run Biotechnology Inc., a leading bio-pharmaceutical company in China engaged in manufacturing and sales of peptide-based and small molecule drugs, today announced it has received the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA). Entecavir is an oral antiviral drug used in the treatment of Hepatitis-B infection. The drug received U.S. Food and Drug Administration (FDA) approval on March 30, 2005 for the treatment of chronic Hepatitis-B infection in adults. The SFDA gave Hainan Zhonghe Pharmaceutical approval to produce Entecavir tablets under the brand names HeDing and HeEn on May 26, 2010, making it…

Continue Reading

ThursdayJun 17, 2010 3:39 pm

Blue Dolphin Energy Company (BDCO) Acquires Interest in Offshore Indonesian Field

Blue Dolphin Energy Company announced that the company has acquired a 70% working interest in a Technical Assistance Contract (TAC) covering an offshore exploration field in Indonesia. The deal closed on June 1, 2010. The Langsa offshore block comprises 77 square kilometers, and is located in the Sumatra Basin, Indonesia. The company said that 4 wells have been drilled to date in this block, with 1 well active and 3 idle at the current time. Blue Dolphin Energy Company said that the one working well on the block is currently producing 620 barrels oil equivalent (BOE) per day, with proved…

Continue Reading

ThursdayJun 17, 2010 3:37 pm

Lucas Energy, Inc. (LEI) Acquires Additional Acreage in Texas

Lucas Energy, Inc. announced that the company has acquired additional oil and gas producing acreage in the Eagle Ford Shale in South Texas. The company said that it would focus on the Buda and Austin Chalk formations on this acreage. Lucas Energy, Inc. bought the properties from several different sellers and acquired nine producing wells in the transaction. The company has already deployed a workover rig to help boost production from these wells. William A. Sawyer, the CEO of Lucas Energy, Inc., said, “The acquisitions continue our business plan model to acquire and re-enter old wells and put them back…

Continue Reading

ThursdayJun 17, 2010 1:07 pm

Neurocrine Biosciences (NBIX) and Abbott (ABT) Team Up to Commercialize Novel Endometriosis/Uterine Fibroid Drug Elagolix

Abbott, www.abbott.com - one of the undisputed global health care leaders with proficiencies in pharmaceuticals, nutritionals, diagnostics and devices, and Neurocrine Biosciences, Inc. (NBIX), www.neurocrine.com – the biopharma developer focused on endocrine and neurological disease/disorders, announced entry into a collaborative agreement for developing and bringing the new endometriosis-related pain treatment, Elagolix, to full commercialization. Elagolix is a gonadotropin-releasing hormone (GnRH) antagonist which inhibits receptors in the pituitary gland, giving it a unique functionality as an estrogen delimiter which is able to relieve symptoms without the typical adverse side effects. Elagolix is a first-in-class oral 8 preparation which has shown pain…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered